HUP0000921A2 - Thyromimetikus elhízás elleni szerek - Google Patents

Thyromimetikus elhízás elleni szerek

Info

Publication number
HUP0000921A2
HUP0000921A2 HU0000921A HUP0000921A HUP0000921A2 HU P0000921 A2 HUP0000921 A2 HU P0000921A2 HU 0000921 A HU0000921 A HU 0000921A HU P0000921 A HUP0000921 A HU P0000921A HU P0000921 A2 HUP0000921 A2 HU P0000921A2
Authority
HU
Hungary
Prior art keywords
group
atom
cycloalkyl
hydrogen atom
alkyl group
Prior art date
Application number
HU0000921A
Other languages
English (en)
Inventor
Peter Cornelius
Diane Marie Hargrove
Bradley Paul Morgan
Andrew Gordon Swick
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0000921D0 publication Critical patent/HU0000921D0/hu
Publication of HUP0000921A2 publication Critical patent/HUP0000921A2/hu
Publication of HUP0000921A3 publication Critical patent/HUP0000921A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

A találmány tárgyát az (I) általános képletű vegyületek és azokgyógyászatilag elfogadható sói, racemátjai és enantiomerjei és azezeket tartalmazó gyógyszerkészítmények képezik, amelyeknél aképletben R jelentése hidroxi-csoport, észterezett hidroxi-csoportvagy éterezett hidroxi-csoport, R1 és R2 jelentése halogénatom,trifluor-metil-csoport vagy -alkilcsoport, R3 jelentése halogénatom,trifluor-metil-csoport, a1kil-, alkanoil-, hidroxi-alkil-, aril-,aril-alkil-, cikloalkil- vagy cikloalkil-, karbociklusos aril-metil-,karbociklusos aril- vagy karbociklusos aril-hidroxi-metil-csoport,vagy R3 jelentése egy (a) általános képletű csoport, amelyben R8jelentése hidrogénatom, alkil-, cikloalkil-, aril-alkil vagycikloalkil-csoport, R9 jelentése hidroxi- vagy acil-oxi-csoport, R10jelentése hidrogénatom vagy alkilcsoport, vagy R9 és R10 a hozzájukkapcsolódó szénatommal együtt egy karbonil-csoportot alkotnak, R4jelentése hidrogénatom, halogénatom; trifluor-metil-csoport vagyalkilcsoport, R5 és R6 jelentése hidrogénatom vagy alkilcsoport, vagyR5 és R6 a hozzájuk kapcsolódó szénatommal együtt karbonilcsoportotalkotnak, X jelentése oxigénatom, kénatom vagy NR7 általános képletűcsoport ahol R7 jelentése hidrogénatom vagy kis szénatomszámúalkilcsoport, W jelentése oxigénatom vagy kénatom, és Z jelentésekarboxilcsoport vagy gyógyászatilag elfogadható észter- illetve amid-formában jelenlévő karboxil-csoport származék. Ó
HU0000921A 1999-03-01 2000-02-28 Thyromimetic antiobesity agents HUP0000921A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12201599P 1999-03-01 1999-03-01

Publications (3)

Publication Number Publication Date
HU0000921D0 HU0000921D0 (en) 2000-04-28
HUP0000921A2 true HUP0000921A2 (hu) 2000-12-28
HUP0000921A3 HUP0000921A3 (en) 2004-06-28

Family

ID=22400061

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000921A HUP0000921A3 (en) 1999-03-01 2000-02-28 Thyromimetic antiobesity agents

Country Status (15)

Country Link
US (2) US6344481B1 (hu)
EP (1) EP1036564B1 (hu)
JP (1) JP2000256190A (hu)
KR (1) KR100368354B1 (hu)
AT (1) ATE282410T1 (hu)
AU (1) AU1635300A (hu)
CA (1) CA2299972C (hu)
CO (1) CO5150235A1 (hu)
DE (1) DE60015831T2 (hu)
ES (1) ES2233282T3 (hu)
HU (1) HUP0000921A3 (hu)
IL (1) IL134382A0 (hu)
NZ (1) NZ503122A (hu)
PE (1) PE20001539A1 (hu)
ZA (1) ZA200001000B (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
EP1496838B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
WO2005051298A2 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1730310A2 (en) * 2004-03-22 2006-12-13 The Regents Of The University Of California A formulation for increasing endogenous adiponectin and leptin production
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
JP2008545711A (ja) * 2005-05-26 2008-12-18 メタバシス・セラピューティクス・インコーポレイテッド 新規ホスフィン酸含有甲状腺ホルモン様剤
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
CA2619770A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AU2006304836A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
JP4371164B2 (ja) 2005-11-10 2009-11-25 萬有製薬株式会社 アザ置換スピロ誘導体
WO2007132475A1 (en) * 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EA201170615A1 (ru) 2008-10-27 2011-12-30 Кадила Хелзкэр Лимитед Лиганды рецептора тиреоидного гормона
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
AU2010240200B2 (en) 2009-04-20 2014-03-13 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone beta receptor agonist
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9401828B2 (en) 2010-05-20 2016-07-26 Kandou Labs, S.A. Methods and systems for low-power and pin-efficient communications with superposition signaling codes
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
MX2015001500A (es) 2012-08-02 2015-04-08 Merck Sharp & Dohme Compuestos antidiabeticos triciclicos.
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
TWI767945B (zh) 2016-10-14 2022-06-21 義大利商Ｔｅｓ製藥（股份）責任有限公司 α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
CN111094554A (zh) 2017-09-14 2020-05-01 国立研究开发法人理化学研究所 视网膜组织的制备方法
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
SG11202109855PA (en) 2019-03-13 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Method for evaluating quality of transplant neural retina, and transplant neural retina sheet
JPWO2022054925A1 (hu) 2020-09-11 2022-03-17
WO2022054924A1 (ja) 2020-09-11 2022-03-17 大日本住友製薬株式会社 移植用組織のための媒体
AU2022390766A1 (en) 2021-11-19 2024-06-20 Riken Production method for sheet-like retinal tissue

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315739B2 (hu) * 1973-10-30 1978-05-26
JPS50124993A (hu) * 1974-03-20 1975-10-01
JPS5937018B2 (ja) * 1978-06-16 1984-09-07 株式会社トクヤマ 難燃化ポリプロピレン組成物
ZA824382B (en) 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
GB8519154D0 (en) 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
GB8714901D0 (en) 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
ES2108855T3 (es) 1992-07-21 1998-01-01 Ciba Geigy Ag Derivados de acido oxamico como agentes hipocolesteremicos.
JPH0834976A (ja) * 1994-07-25 1996-02-06 Asahi Denka Kogyo Kk 潜熱利用型蓄熱材
AU5524896A (en) * 1995-03-20 1996-10-08 Institut Pasteur De Lille Modulators of ob gene and screening methods therefor
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
ATE272609T1 (de) * 1999-03-01 2004-08-15 Pfizer Prod Inc Oxamsäure und deren derivate als liganden der thyroid-rezeptoren
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents

Also Published As

Publication number Publication date
AU1635300A (en) 2000-09-07
CA2299972C (en) 2003-08-19
CA2299972A1 (en) 2000-09-01
NZ503122A (en) 2001-11-30
KR20010006712A (ko) 2001-01-26
EP1036564B1 (en) 2004-11-17
HUP0000921A3 (en) 2004-06-28
PE20001539A1 (es) 2001-01-08
CO5150235A1 (es) 2002-04-29
ZA200001000B (en) 2001-08-29
IL134382A0 (en) 2001-04-30
US20020035153A1 (en) 2002-03-21
JP2000256190A (ja) 2000-09-19
ES2233282T3 (es) 2005-06-16
KR100368354B1 (ko) 2003-01-24
HU0000921D0 (en) 2000-04-28
DE60015831T2 (de) 2005-12-15
EP1036564A1 (en) 2000-09-20
DE60015831D1 (de) 2004-12-23
US6555578B2 (en) 2003-04-29
ATE282410T1 (de) 2004-12-15
US6344481B1 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
HUP0000921A2 (hu) Thyromimetikus elhízás elleni szerek
NO20025590D0 (no) Fenylglycin-derivater
ATE188216T1 (de) Therapeutische mittel für die parkinsonsche krankheit
CO5680419A2 (es) Derivados de 1-[(indol-3-il)carbonil] piperazinas
HUP0103366A2 (hu) Citokin inhibítorként használható amidszármazékok
HUP0301330A2 (hu) 2-Aminokarbonil-9H-purin-származékok
HUP0303652A2 (hu) Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények
DE69314718D1 (de) Oxamidsäure-Derivate als hypocholesterämische Mittel
DE3789967D1 (de) Anwendung von monoaminakridinen bei mangelerscheinungen des cholinergen nervensystems.
HUP0301777A2 (hu) Tiroidreceptor-ligandum anilin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9903707A2 (hu) 17Béta-karboxi-,-tio-karboxi-vagy -amido-androsztánszármazékok laktonszármazékai, előállításuk, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0002031A2 (hu) Benzotiofénszármazékok alkalmazása központi idegrendszeri betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
ES538418A0 (es) Un derivado de indol-3-carboxamida
HUP0002330A2 (hu) Azetidinilpropilpiperidin-származékok, ezek intermedierjei és tachikinin antagonistaként történő alkalmazásuk
HUP0100680A2 (hu) Indolszármazékok és azokat tartalmazó gyógyszerkészítmények
NO892338L (no) Middel for insekt- og middbekjempelse.
HUP0101469A2 (hu) 5-[(2-Imidazolidinilidén)-amino]-benzimidazol-származékok, előállításuk és alkalmazásuk javított metabolikus stabilitású alfa-adrenoceptor agonistákként
TW355709B (en) Quinoline carboxylic acid derivative
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
NZ505200A (en) Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
DE60000978D1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
ATE336487T1 (de) Benzoesaüre derivate und deren verwendung
AR010205A1 (es) Un compuesto farmaceutico
DK0802920T3 (da) Fusacandin-antisvampemidler
HUP0204144A2 (en) N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses